AMYLON THERAPEUTICS
Amylon Therapeutics is a biotechnology company that uses RNA Modulation Technology to target rare genetic disorders of the central nervous system (CNS). Our mission is to deliver on the potential of our technology by developing life-changing therapeutic solutions for patients with serious unmet medical need. We have high ambitions and want to change the way the world looks at neurological disorders. The enormous burden these diseases put on patients and their loved ones is unacceptable and somet... hing we strive to change every day. We believe that every patient deserves the hope for a brighter future. Our vision is to build a sustainable drug development platform in which the whole is bigger than the sum of its parts. This will allow us to focus on CNS diseases large and small and hopefully leave no patient untreated.
AMYLON THERAPEUTICS
Social Links:
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2017-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.amylontx.com
Total Employee:
1+
Status:
Closed
Contact:
020-4044707
Email Addresses:
[email protected]
Total Funding:
300 K EUR
Technology used in webpage:
Domain Not Resolving Person Schema Gravatar Profiles Dutch Server Location
Similar Organizations
Beren Therapeutics
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Tramontane Therapeutics
Tramontane Therapeutics is a gene therapy company creates solutions for common neurological and metabolic illnesses.
Founder
Investors List
UNIIQ
UNIIQ investment in Seed Round - Amylon Therapeutics
Official Site Inspections
http://www.amylontx.com
- Host name: 192.64.119.158
- IP address: 192.64.119.158
- Location: Los Angeles United States
- Latitude: 34.0318
- Longitude: -118.4252
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90064
More informations about "Amylon Therapeutics"
Amylon Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 020-4044707 Amylon Therapeutics is a biotechnology company that uses RNA Modulation Technology to target rare genetic disorders โฆSee details»
Amyl
Amyl Therapeutics is a preclinical-stage biotech company developing Pan-Amyloid Immunotherapy (PAI), a universal treatment for amyloid-mediated diseases.See details»
Pillar VC Team | Experienced Operators Supporting Scientists
Thomas wants to help founders bring new innovations to patients. Thomas has spent most of his career building biotech companies. Prior to Pillar VC, Thomas was at Flagship Pioneering, โฆSee details»
Amylon Therapeutics - VentureRadar
Website: http://amylontx.com. Develops therapies for rare genetic central nervous system disorders, with a focus on Hereditary Cerebral Hemorrhage with Amyloidosis ...See details»
Amylon Therapeutics - Leiden, Netherlands - bionity.com
Nov 9, 2017 amylontx.com. Contact. Profile Products News. Contact. About Amylon Therapeutics. Amylon Therapeutics targets CNS disorders through an ultra-genetics โฆSee details»
Amylon 2025 Company Profile: Valuation, Funding & Investors
Amylon General Information Description. Developer of a drug development platform designed for rare genetic disorders of the central nervous system. The company's platform is based on โฆSee details»
Amylon Therapeutics B.V. - life-sciences-europe.com
Sep 12, 2017 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl โ the European Association of Bioindustries; BioIndustry โฆSee details»
Amylon Therapeutics BV - Drug pipelines, Patents, Clinical trials
Explore Amylon Therapeutics BV with its drug pipeline, therapeutic area, technology platform, 1 literature, Disease Domain:Nervous System Diseases, Technology Platform:Biological โฆSee details»
Amylon Therapeutics | IT History Society
Amylon Therapeutics is a biotechnology company that targets CNS disorders through an ultra-genetics approach.Amylon Therapeutics is a biotechnology company that targets CNS โฆSee details»
ProQR spins out CNS assets to form RNA rare disease biotech
Sep 13, 2017 ProQR has spun out its CNS assets to form Amylon Therapeutics. The offshoot starts life with seed funding and an RNA-based program targeting a rare genetic disease that โฆSee details»
ProQR spins out Amylon Therapeutics as a privately-held company โฆ
Key updates. ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has โฆSee details»
Amylon Therapeutics - VentureRadar
Similar Companies: Latus Bio USA Privately Held Latus Bio, Inc. is a biotechnology company focused on developing novel gene therapy candidates for central nervous system (CNS) โฆSee details»
AT-01 (Amylon) - Drug Targets, Indications, Patents - Synapse
Active Organization-Inactive Organization. Amylon Therapeutics, Inc. Drug Highest Phase Pending Preclinical. First Approval Date-Regulation-Structure/Sequence. Boost your research โฆSee details»
Amylon Therapeutics-ๅจ่็ฝ - vbdata.cn
[email protected] Amylon Therapeuticsๆฏไธๅฎถ็็ฉๆๆฏๅ ฌๅธ๏ผ้่ฟ่ถ ้ไผ ๅญฆๆนๆณ้ๅฏนCNS็พ็ ๏ผไธๆณจไบ็ฝ่ง็้ไผ ็พ็ ๏ผๅฏไฝไธบๆด้ข็นๅ็้ๅบ็็ๅฏ่ฝ้ๅพใ ไผไธ็ปๅSee details»
Amylon Therapeutics B.V. - life-sciences-europe.com
Upcoming Events. ADLM 2024 Annual Meeting & Clinical Lab Expo Chicago (formerly AACC 2024) IMSC 2024 Melbourne; Pharmatech & Health East Africa 2024 with Medical & Lab East โฆSee details»
News - Amyl
This occasion also marks an important leadership transition within our organization. We are delighted to introduce Damien Toulorge, our new Chief Scientific Officer(CSO). Damien brings โฆSee details»
Andrew Brynes - Altruix Chief Financial Officer
Eric is leveraging the full power of the organizationโs behavioral health expertise, growing physical presence, data, and innovative technology to unleash a pharmacy platform that improves โฆSee details»
Reset
ResetSee details»
Amlogenyx - Crunchbase Company Profile & Funding
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease. It is a spin-off from Ultragenyx Pharmaceutical.See details»
ALS Association, I AM ALS Call on Amylyx, FDA to Make Promising โฆ
Dec 30, 2020 The phase 2 trial included 137 people with ALS across 25 medical centers that are part of the Northeast ALS (NEALS) continuum. People with ALS who received AMX0035 โฆSee details»